Buzz Update Oxygen to commercialize Bharat Biotech’s Kovacsin in Mexico TOU

Buzz Update Oxygen to commercialize Bharat Biotech’s Kovacsin in Mexico

 TOU

Oxygen to commercialize Bharat Biotech’s Kovacsin in Mexico

Ocugen, Inc and Bharat Biotech International Ltd have modified their current co-development, supply and commercialization agreement to include the Kovid-19 vaccine Kovacin‌ in the US and Canada in Mexico.

With this amendment, Ocugen now owns the commercial rights to Kovacsin throughout North America.

“We are excited to commercialize covaxin in Mexico because the authorities there have made conquering this epidemic a top priority. Executive Officer and Co-Founder, Ocugen said in a statement.

“Covaxin is currently being reviewed by COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) for emergency use in children between the ages of 2 and 18 and Ocugen is ready to cooperate with the public health community to assist in their efforts,” he added.

“We are pleased to announce our partnership with Okugen for Mexico as well as the United States and Canada. It is clear from its global introduction that Kovacin is a safe and effective inactivated vaccine for all ages,” said Krishna Ella, Chairman and Managing Director, Bharat Biotech.

“We fully support Team Ocugen in our effort to accelerate technology transfer operations for the commercial scale manufacturing of Covaxin in North America,” Ella added.

The license extension between Ocugen and Hyderabad-based Bharat Biotech for commercialization in Mexico has the same profit share structure as in the United States. Under the previous agreement, Ocugen would receive a 45 percent stake in the profits.

Kovacsin ‘ideal’ vaccine choice for Mexico at this stage of the epidemic. As a whole virion, inactivated vaccine, it acquires strong cellular immunosuppression to SARS-CoV-2 and variant of Concern. It offers the logistical benefits of supporting vaccine access in hard-to-reach communities, the release said.

Published

April 18, 2022

if you want to read this article from the original credit source of the article then you can read from here.

Leave a Reply